Recomendations for the use of erlotinib (Tarceva) in patients with liver disease
Letter dated December 12, 2008 published on the Health Canada website on erlotinib adverse effects: Dear Health Care Professional, Hoffmann-La Roche Limited, in consultation with Health Canada would like to inform prescribers of important new safety information regarding the use of TARCEVA® (erlotinib) in patients with moderate hepatic impairment and advanced solid tumors. TARCEVA is […]